Japan Approves Groundbreaking Treatments Using Reprogrammed Human Cells

On March 6, 2026, Japan’s Ministry of Health, Labor, and Welfare granted conditional marketing authorization for two innovative medical products derived from induced pluripotent stem (iPS) cells, marking a significant milestone in regenerative medicine. This decision coincides with the 20th anniversary of the creation of iPS cells, which were first developed by Shinya Yamanaka, a professor at Kyoto University. The approved treatments, ReHeart and Amusepri, aim to provide new therapeutic options for patients suffering from severe heart failure and Parkinson’s disease, respectively.

World’s First Treatment Made from Reprogrammed Human Cells Approved in JapanWired Magazine

ReHeart, developed by Qualipse, a startup from Osaka University, involves transplanting sheets of cardiomyocytes—heart cells differentiated from healthy donor iPS cells—onto the hearts of patients with severe ischemic cardiomyopathy. This approach offers a less invasive alternative to traditional heart failure treatments, which often require heart transplants that face donor shortages. Early clinical trials have shown promising results, with patients experiencing significant improvements in oxygen consumption levels.

World’s First Treatment Made from Reprogrammed Human Cells Approved in Japan

Amusepri targets Parkinson’s disease by using precursor cells derived from iPS cells to replace lost dopamine-producing neurons in the brain. This treatment represents a potential breakthrough, as it aims to address the underlying causes of the disease rather than merely alleviating symptoms. Clinical trials have indicated improvements in motor functions for patients who did not respond to conventional therapies, although the procedure involves minimally invasive surgery to implant the precursor cells directly into the brain.

World’s First Treatment Made from Reprogrammed Human Cells Approved in JapanWired Magazine

Shinya Yamanaka expressed optimism regarding the approval, stating, “We are very pleased to have taken a major step toward social application on the 20th anniversary of the announcement of mouse iPS cells.” However, he emphasized the necessity of further research to confirm the safety and efficacy of these treatments. Kenichiro Ueno, Japan’s Minister of Health, Labor, and Welfare, also highlighted the significance of this achievement, noting, “I hope it will help patients not only in Japan but all over the world.”

World’s First Treatment Made from Reprogrammed Human Cells Approved in Japan

Despite the excitement surrounding these approvals, experts caution that the journey is far from complete. Yamanaka reiterated the importance of ongoing clinical trials to ensure the treatments are safe and effective for broader patient populations. Jun Takahashi, director of the iPS Cell Research Institute, echoed this sentiment, stating, “Even if approval is granted, that is not the goal, but only the beginning of this new medicine.”

World’s First Treatment Made from Reprogrammed Human Cells Approved in Japan

The approval of ReHeart and Amusepri signifies a transformative moment in healthcare, reflecting Japan’s commitment to advancing regenerative medicine through collaboration among academia, industry, and government. As these treatments transition from research to clinical practice, they hold the potential to significantly impact the lives of patients worldwide, heralding a new era in personalized, cell-based therapies.

World’s First Treatment Made from Reprogrammed Human Cells Approved in Japan